[February 15, 2012]

Anacor Pharmaceuticals to Present at Upcoming Investor Conferences

Anacor Pharmaceuticals announced today that David Perry, the company's Chief Executive Officer, will provide a company overview at the following upcoming investor conferences:

• Citi Global Health Care Conference on Monday February 27, 2012 at 11:30 a.m. ET in New York, New York.
• RBC Global Healthcare Conference on Tuesday February 28, 2012 at 8:00 a.m. ET in New York, New York.
• Cowen and Company 32nd Annual Health Care Conference on Wednesday March 7, 2012 at 9:20 a.m. ET in Boston, Massachusetts.

All events will be webcast live and may be accessed under "Events and Presentations" on the Investors page of Anacor's website at www.anacor.com. A replay will also be available for three months following each presentation.

About Anacor Pharmaceuticals

Anacor is a biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. Anacor has discovered six compounds that are currently in development including its three lead programs: tavaborole, a topical antifungal for the treatment of onychomycosis; AN2728, a topical anti-inflammatory PDE-4 inhibitor for the treatment of psoriasis and atopic dermatitis; and GSK 2251052, or GSK '052 (formerly referred to as AN3365), a systemic antibiotic for the treatment of infections caused by Gram-negative bacteria, which has been licensed to GlaxoSmithKline under the companies' research and development agreement. Anacor is also developing AN2718 as a topical antifungal product candidate for the treatment of onychomycosis and skin fungal infections and AN2898 as a topical anti-inflammatory product candidate for the treatment of psoriasis and atopic dermatitis. In addition, AN8194 has been licensed by Eli Lilly and Company and is in development for an animal health application. For more information, visit http://www.anacor.com.

[ Back To TMCnet.com's Homepage ]